Fentanyl sublingual spray for breakthrough cancer pain in patients receiving transdermal fentanyl
| dc.contributor.author | Alberts, David S | |
| dc.contributor.author | Smith, Christina Cognata | |
| dc.contributor.author | Parikh, Neha | |
| dc.contributor.author | Rauck, Richard L | |
| dc.date.accessioned | 2016-12-19T22:34:23Z | |
| dc.date.available | 2016-12-19T22:34:23Z | |
| dc.date.issued | 2016-10 | |
| dc.identifier.citation | Fentanyl sublingual spray for breakthrough cancer pain in patients receiving transdermal fentanyl 2016, 6 (5):427 Pain Management | en |
| dc.identifier.issn | 1758-1869 | |
| dc.identifier.issn | 1758-1877 | |
| dc.identifier.doi | 10.2217/pmt-2015-0009 | |
| dc.identifier.uri | http://hdl.handle.net/10150/621765 | |
| dc.description.abstract | Aim: To investigate the relationship between effective fentanyl sublingual spray (FSS) doses for breakthrough cancer pain (BTCP) and around-the-clock (ATC) transdermal fentanyl patch (TFP). Methods: Adults tolerating ATC opioids received open-label FSS for 26 days, followed by a 26-day double-blind phase for patients achieving an effective dose (100-1600 mu g). Results: Out of 50 patients on ATC TFP at baseline, 32 (64%) achieved an effective dose. FSS effective dose moderately correlated with mean TFP dose (r = 0.4; p = 0.03). Patient satisfaction increased during the study. Common adverse events included nausea (9%) and peripheral edema (9%). Conclusion: FSS can be safely titrated to an effective dose for BTCP in patients receiving ATC TFP as chronic cancer pain medication. ClinicalTrials.gov identifier: NCT00538850 | |
| dc.language.iso | en | en |
| dc.publisher | FUTURE MEDICINE LTD | en |
| dc.relation.url | http://www.futuremedicine.com/doi/10.2217/pmt-2015-0009 | en |
| dc.rights | Copyright © David S Alberts, MD, & co-authors. This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. | en |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.subject | breakthrough cancer pain | en |
| dc.subject | fentanyl sublingual spray | en |
| dc.subject | transmucosal immediate-release fentanyl | en |
| dc.title | Fentanyl sublingual spray for breakthrough cancer pain in patients receiving transdermal fentanyl | en |
| dc.type | Article | en |
| dc.contributor.department | University of Arizona | en |
| dc.identifier.journal | Pain Management | en |
| dc.description.note | Authors chose open access article option (hybrid journal). | en |
| dc.description.collectioninformation | This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu. | en |
| dc.eprint.version | Final published version | en |
| refterms.dateFOA | 2018-06-14T04:39:24Z | |
| html.description.abstract | Aim: To investigate the relationship between effective fentanyl sublingual spray (FSS) doses for breakthrough cancer pain (BTCP) and around-the-clock (ATC) transdermal fentanyl patch (TFP). Methods: Adults tolerating ATC opioids received open-label FSS for 26 days, followed by a 26-day double-blind phase for patients achieving an effective dose (100-1600 mu g). Results: Out of 50 patients on ATC TFP at baseline, 32 (64%) achieved an effective dose. FSS effective dose moderately correlated with mean TFP dose (r = 0.4; p = 0.03). Patient satisfaction increased during the study. Common adverse events included nausea (9%) and peripheral edema (9%). Conclusion: FSS can be safely titrated to an effective dose for BTCP in patients receiving ATC TFP as chronic cancer pain medication. ClinicalTrials.gov identifier: NCT00538850 |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as Copyright © David S Alberts, MD, & co-authors. This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.